Methylglyoxal modification of LDL: Proatherogenicity without oxidation opens new paths to prevent cardiovascular disease

Clinical Lipidology

Volumn 6, Issue 6, 2011, Pages 631-634

  Thornalley, Paul J ^a   Rabbani, Naila ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

aging; cardiovascular disease; diabetes; dicarbonyl stress; glycation; glyoxalase; LDL; methylglyoxal; oxidative stress; renal failure

Indexed keywords

ALPHA TOCOPHEROL; AMINOGUANIDINE; ANTIOXIDANT; APOLIPOPROTEIN B100; ASCORBIC ACID; BETA CAROTENE; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; GLUCOSE; IRBESARTAN; LACTOYLGLUTATHIONE LYASE; LOW DENSITY LIPOPROTEIN; METFORMIN; METHYLGLYOXAL; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEOGLYCAN; THIAMINE; TRANSKETOLASE; TRIACYLGLYCEROL;

ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIOTRANSFORMATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG MEGADOSE; GLUCOSE METABOLISM; HUMAN; LIPID OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; PROTEIN MODIFICATION; REVIEW; VITAMIN SUPPLEMENTATION;

EID: 82755173975     PISSN: 17460875     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.11.53     Document Type: Review

References (24)

1. Bitton A, Gaziano T. The Framingham heart studys impact on global risk assessment. Prog. Cardiovasc. Dis. 53, 68-78 (2010).
2. Sarwar N, Gao P, Seshasai SRK et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375, 2215-2222 (2010).
3. Rizzo M, Berneis K, Corrado E, Novo S. The significance of low-density-lipoproteins size in vascular diseases. Int. Angiolo. 25, 4-9 (2006).
4. Rizzo M, Berneis K, Koulouris S et al. Should we measure routinely oxidized and atherogenic dense low-density lipoproteins in subjects with Type 2 diabetes? Int. J. Clin. Prac. 64, 1632-1642 (2010).
5. Anber V, Millar JS, McConnell M, Shepherd J, Packard CJ. Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans. Arterioscler. Thromb. Vasc. Biol. 17, 2507-2514 (1997). (Pubitemid 28015987)
6. Galeano NF, Al Haideri M, Keyserman F, Rumsey SC, Deckelbaum RJ. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J. Lipid Res. 39, 1263-1273 (1998). (Pubitemid 28270090)
7. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362, 801-809 (1993). (Pubitemid 23132154)
8. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part III: mechanistically defining the role of hyperlipidemia. J. Lipid Res. 46, 2037-2051 (2005 (Pubitemid 41377456)
9. Scheffer PG, Bos G, Volwater HGFM, Dekker JM, Heine RJ, Teerlink T. Associations of LDL size with in vitro oxidizability and plasma levels of in vivo oxidized LDL in Type 2 diabetic patients. Diabet. Med. 20, 563-567 (2003). (Pubitemid 36886471)
10. Roob JM, Rabold T, Hayn M et al. Ex vivo low-density lipoprotein oxidizability and in vivo lipid peroxidation in patients on CAPD. Kidney Int. 59, S128-S136 (2001). (Pubitemid 32144085)
11. Pashkow FJ. Oxidative stress and inflammation in heart disease: do antioxidants have a role in treatment and/or prevention? Int. J. Inflammation 2011, 514623 (2011).
12. Langer T, Levy RI, Strober W. Metabolism of low-density lipoprotein in familial type-H hyperlipoproteinemia. J. Clin. Investig. 51, 1528-1536 (1972).
13. Rabbani N, Thornalley PJ. Glyoxalase in diabetes, obesity and related disorders. Semin. CellDev. Biol. 22, 309-317 (2011).
14. Thornalley PJ, Rabbani N. Highlights and hotspots of protein glycation in end-stage renal disease. Semin. Dial. 22, 400-404 (2009).
15. Thornalley PJ. Dicarbonyl intermediates in the Maillard reaction. Ann. N.Y. Acad. Sci. 1043, 111-117 (2005). (Pubitemid 41123896)
16. Rabbani N, Varma Chittari M, Bodmer CW, Zehnder D, Ceriello A, Thornalley PJ. Increased glycation and oxidative damage to apolipoprotein B100 of LDL in patients with Type 2 diabetes and effect of metformin. Diabetes 59, 1038-1045 (2010).
17. Rabbani N, Godfrey L, Xue M et al. Conversion of low density lipoprotein to the pro-atherogenic form by methylglyoxal with increased arterial proteoglycan binding and aortal retention. Diabetes 60, 1973-1980 (2011).
18. Anber V, Millar JS, McConnell M, Shepherd J, Packard CJ. Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans. Arterioscler. Thromb. Vasc. Biol. 17, 2507-2514 (1997). (Pubitemid 28015987)
19. Steinbrecher UP, Witztum JL. Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 33, 130-134 (1984). (Pubitemid 14184698)
20. Xue M, Rabbani N, Thornalley PJ. Glyoxalase in ageing. Semin. CellDev. Biol. 22, 293-301 (2011).
21. Rabbani N, Thornalley PJ. Emerging role of thiamine therapy for prevention and treatment of early-stage diabetic nephropathy. Diabet. Obes. Metab. 13, 577-583 (2011).
22. Forbes JM, Yee LTL, Thallas V et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53, 1813-1823 (2004).
23. Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch. Biochem. Biophys. 419, 31-40 (2003). (Pubitemid 37279141)
24. Thornalley PJ, Minhas HS. Rapid hydrolysis and slow a,b-dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links. Biochem. Pharmacol. 57, 303-307 (1999 (Pubitemid 29056208)